• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjects

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    Predicting longer-term progression-free survival (PFS) with durvalumab after chemoradiotherapy (CRT) in unresectable stage III NSCLC using a mixture cure model (MCM)

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Thumbnail
    Name:
    Faivre-Finn.pdf
    Size:
    116.9Kb
    Format:
    PDF
    Description:
    From UNPAYWALL
    Download
    Authors
    Faivre-Finn, C.
    Jackson, D.
    Abrams, K. R.
    Hawkins, N. S.
    Thiyagarajah, P.
    Zhang, Y.
    Hettle, R.
    Dunlop, W.
    Spigel, D. R.
    Affiliation
    The University of Manchester and The Christie NHS Foundation Trust, Manchester, UK
    Issue Date
    2021
    
    Metadata
    Show full item record
    Abstract
    Background Five-year results from the placebo-controlled phase 3 PACIFIC trial (NCT02125461) demonstrated robust and sustained overall survival (OS) and durable PFS benefit with durvalumab (given every 2 weeks up to 12 months) in pts with unresectable Stage III non-small-cell lung cancer (NSCLC) and no disease progression after platinum-based concurrent CRT. Given the potential for longer-term PFS gain in this curative-intent setting, we used MCM analysis, a common statistical model in such settings, to predict the potential longer-term PFS benefit with durvalumab. Methods Pt-level data from 5 years follow-up in PACIFIC were used. MCMs were fitted to PFS data (BICR; RECIST v1.1) to estimate the proportion of pts who are ‘long-term survivors’ (the statistical cure fraction, defined as the proportion of pts with no risk of disease progression) in each arm. Treatment benefit for the non-cured proportion was also modelled. Model estimates were then used to predict 10-year PFS probabilities (‘rates’), while adjusting for background mortality. Models assuming no cure were fitted as sensitivity analyses. Results The MCM reported a consistent benefit with durvalumab versus placebo at 10 years with different parametric models and fitted better than non-cure models. The best fitting model used log-normal distribution for pts at risk of progression. Using this model, the estimated statistical cure fraction for PFS was 36.0% (95% CI, 30.2–42.3) with durvalumab and 19.4% (13.7–26.6) with placebo. When accounting for background mortality, the estimated 10-year PFS rate (95% CI) was 28.7% (24.3–33.5) and 15.4% (11.1–21.0), respectively. Similar analysis applying 5-year OS data to both cure and non-cure models also demonstrated longer-term benefit with durvalumab. Conclusions MCMs had a good statistical fit with PACIFIC 5-year PFS data. The best fitting cure model estimated a 10-year PFS rate of >25% with durvalumab, almost twice the rate estimated with best supportive care only (i.e. placebo). These analyses, while modelled predictions based on PFS, may assist oncologists with understanding longer-term outcomes in unresectable, Stage III NSCLC.
    Citation
    Faivre-Finn C, Jackson D, Abrams KR, Hawkins NS, Thiyagarajah P, Zhang Y, et al. Predicting longer-term progression-free survival (PFS) with durvalumab after chemoradiotherapy (CRT) in unresectable stage III NSCLC using a mixture cure model (MCM). Annals of Oncology. 2021;32:S1408-S9.
    Journal
    Annals of Oncology
    URI
    http://hdl.handle.net/10541/624996
    DOI
    10.1016/j.annonc.2021.10.102
    Additional Links
    https://dx.doi.org/10.1016/j.annonc.2021.10.102
    Type
    Meetings and Proceedings
    Language
    en
    ae974a485f413a2113503eed53cd6c53
    10.1016/j.annonc.2021.10.102
    Scopus Count
    Collections
    All Christie Publications

    entitlement

     
    DSpace software (copyright © 2002 - 2023)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.